Organisation paid for research Program year 2024 Source: CMS Open Payments

Columbus Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$502,355

188 payments

Through program year 2024, Columbus Research Group LLC is reported as receiving $502,355 in research payments, across 188 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$7,212	2
2023	Research	$69,131	15
2022	Research	$29,092	7
2021	Research	$57,933	23
2020	Research	$131,106	32
2019	Research	$207,881	109

Breakdown

Who paid Research payments · program years 2019–2024

Akebia Therapeutics Inc $230,806 130 payments
GlaxoSmithKline, LLC. $187,313 38 payments
Bayer HealthCare Pharmaceuticals Inc. $59,948 17 payments
AstraZeneca Pharmaceuticals LP $24,287 3 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3 Randomized, Double-Blind, Active-Controlled, Parallel-Group, $120,322 24 payments
Akb-6548-Ci-0014 $99,829 88 payments
A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou $66,991 14 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $42,555 5 payments
Akb-6548-Ci-0014 $42,285 18 payments
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects $31,825 5 payments
BAY94-8862 Finerenone Phase 3 in non-diabetic CKD $29,092 7 payments
BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $23,644 8 payments
TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $13,661 2 payments
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $10,626 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.